Cardiogenic shock following recombinant alpha-2b interferon therapy for chronic hepatitis C: A case report

Japanese Heart Journal

Volumn 37, Issue 1, 1996, Pages 137-142

  Teragawa, Hiroki ^a   Hondo, Tatsuya ^a   Amano, Hajime ^a   Watanabe, Hiroshi ^a   Ohe, Hirotoki ^a   Hattori, Nobuaki ^a   Watanabe, Yasunori ^a   Hino, Fumiaki ^a   Ohbayashi, Makoto ^a  

^a Onomichi General Hospital   (Japan)

Author keywords

Acute myocarditis; Complete atrioventricular block; Pericardial effusion; Regional wall motion abnormality

Indexed keywords

ANTIVIRUS AGENT; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CARDIOGENIC SHOCK; CASE REPORT; CLINICAL FEATURE; COMPLETE HEART BLOCK; FEMALE; HEPATITIS C; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MYOCARDITIS; PERICARDIAL EFFUSION; PRIORITY JOURNAL;

ACUTE DISEASE; BLOOD TRANSFUSION; FEMALE; HEART BLOCK; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON ALFA-2B; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDITIS; PERICARDIAL EFFUSION; SHOCK, CARDIOGENIC;

EID: 0029886007     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.37.137     Document Type: Article

References (18)

1. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha. New Engl J Med 1989; 321: 1501-6.
2. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C. New Engl J Med 1506, 1989; 321: 1506-10.
3. Hoofnagle JH, Di Bisceglie AM. Treatment of chronic type C hepatitis with alpha interferon. Semin Liver Dis 1989; 9: 259-63.
4. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin liver Dis 1989; 9: 273-7.
5. Taniguchi Y, Murakami T, Nakanishi K, et al. Two cases of hypothyroidism associated with alpha-interferon therapy. Internal Med 1992; 31: 373-6.
6. Sakai T, Ozawa H, Saeki K, et al. The clinical evaluation on the cardiovascular complications of interferon. Shinzo 1995; 27: 62-9. (In Japanese)
7. Yamazaki K, Amishita M, Fujita J, et al. A case of chronic hepatitis C complicated by ishemia-like changes seen on the electrocardiogram during interferon treatment. Kokyu to Junkan 1993; 41: 805-9. (In Japanese with English abstract)
8. Kouno H, Aimitsu S, Ikemoto Y, et al. Cardiovascular complications of interferon therapy for chronic hepatitis C. Nipponrinsho 1994; 52: 1914-8. (In Japanese with English abstract)
9. Shimazaki H, Kawada N, Yasuda S, et al. A case of hepatitis C complicated with diabetes mellitus and cardiomyopathy after interferon therapy. Clin Gastroent 1993; 8. 1897-900. (in Japanese)
10. Kirkwood JM, Ernstoff MS. Interferons in the treatment of human cancer. J Clin Oncol 1984; 2: 336-52.
11. Grunberg SM, Kempf RA, Itri LM, et al. Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma. Cancer Treat Rep 1985; 69: 1031-2.
12. Sonnenblick M, Rosin A. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 99: 557-61.
13. Kobayashi T, Sato Y, Hasegawa Y, et al. Multiple myeloma complicated by congestive heart failure following first administration of recombinant alpha interferon. Internal Med 1992; 31: 936-40.
14. Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by interferon. BMJ 1990; 300: 1174-5.
15. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med 1988; 85: 549-51.
16. Merimsky O, Inbar M, Merimsky E, et al. Phase II study of recombinant interferon alpha-C in patients with metastatic renal cell carcinoma. Mol Biother 1990; 2: 155-9.
17. Cooper MR, Fefer A, Thompson J, et al. Alpha-2 interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: A phase I-II trial. Cancer Treat Rep 1986; 70: 473-6.
18. Woodruff JF. Viral myocarditis. A review. Am J Pathol 1980; 101: 425-84.